{"publication_id":"3591803f-c88e-47e8-a088-a212f55ad36d","content_hash":"sha256:51f6fa416b0025704cbfd3f46cc50ef90c147d3aa703b0c2ca0bd412758cb09c","nodes":[{"id":"3591803f-c88e-47e8-a088-a212f55ad36d","type":"publication","title":"SGLT2 inhibitors: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91)"},{"id":"claim_1","type":"claim","text":"The cited direct receipts support a bounded working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01)."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_4","type":"claim","text":"`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836"},{"id":"claim_5","type":"claim","text":"`fact_id=160903` (`A_core`) — SGLT2I use was associated with lower risks of Parkinson's (HR:0.28, 95% CI: [0.09-0.91], P = 0.0349) doi=10.3389/fcvm.2021.747620"},{"id":"claim_6","type":"claim","text":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"},{"id":"claim_7","type":"claim","text":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia doi=10.3390/diseases8020014"},{"id":"claim_8","type":"claim","text":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?"},{"id":"source_1","type":"source","study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","year":2021,"doi":"10.1016/j.phrs.2021.105836","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_2","type":"source","study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","year":2023,"doi":"10.1161/jaha.123.030578","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","year":2021,"doi":"10.3389/fcvm.2021.747620","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","year":2022,"doi":"10.3390/ijms23073651","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","year":2018,"doi":"10.1177/2047487318755531","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_1","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_2","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_3","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_4","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_5","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_6","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_7","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_8","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}